Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Breast Neoplasms 103Carcinoma, Renal Cell 70Neoplasm Metastasis 48Neoplasms 37Neuroendocrine Tumors 33Kidney Neoplasms 27Recurrence 19Tuberous Sclerosis 18Carcinoma, Non-Small-Cell Lung 17Prostatic Neoplasms 16Triple Negative Breast Neoplasms 15Lymphoma 15Lymphoma, Mantle-Cell 14Lymphoma, Large B-Cell, Diffuse 14Head and Neck Neoplasms 14Glioblastoma 14Colorectal Neoplasms 13Carcinoma, Hepatocellular 13Stomach Neoplasms 12Lung Neoplasms 12Leukemia, Lymphocytic, Chronic, B-Cell 12Hodgkin Disease 12Brain Neoplasms 12Sarcoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Glioma 11Waldenstrom Macroglobulinemia 10Lymphoma, Follicular 10Carcinoma, Neuroendocrine 10

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 8Bevacizumab 8toripalimab 7senaparib 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Gemcitabine 5Fluorouracil 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorodeoxyglucose F18 4Carboplatin 4spartalizumab 3sintilimab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Solid Tumor × Everolimus × Clear all
NCT04185831 2024-08-22

MEGALiT

Uppsala University Hospital

Phase 2 Active not recruiting
167 enrolled
Other solid neoplasm

Solid Tumor

NCT02449538 2017-02-17

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Samsung Medical Center

Phase 2 Completed
10 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡